Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

Morgan Stanley analyst Shannon O'Callaghan has maintained an Overweight rating on Guardant Health (NASDAQ: GH) and increased the price target from $185 to $200. This adjustment reflects the firm's positive outlook on the company's performance.